Search Results

(-)-Cevimeline hydrochloride hemihydrate 5 mg  | Purity Not Available

TargetMol

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011) is a novel muscarinic receptor agonist that is a candidate therapeutic drug for xerostomia in Sjogren’s syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro […]

More Information Supplier Page

(-)-Cevimeline hydrochloride hemihydrate 10 mg  | Purity Not Available

TargetMol

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011) is a novel muscarinic receptor agonist that is a candidate therapeutic drug for xerostomia in Sjogren’s syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro […]

More Information Supplier Page

(-)-Cevimeline hydrochloride hemihydrate 2 mg  | Purity Not Available

TargetMol

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011) is a novel muscarinic receptor agonist that is a candidate therapeutic drug for xerostomia in Sjogren’s syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro […]

More Information Supplier Page